Brief: Onxeo H1 Net Loss Widens To EUR 11.5 Mln

Valerio Therapeutics SA

14/09/2022 06:37

Sept 14 (Reuters) - Onxeo SA  ALONX.PA :
    * REPORTED ON TUESDAY H1 RESULTS
    * REFOCUSING R&D EFFORTS AND ACCELERATING PRECLINICAL AND
CLINICAL
PROGRAMS GLOBALLY
    * CASH POSITION OF EUR 26.9 MILLION AS OF JUNE 30, 2022
    * FINANCIAL VISIBILITY ASSURED UNTIL Q2 2023
    * ASIDNA: EXPECTS TO LAUNCH CLINICAL TRIAL IN H2 2022 AT 3
TO 5
POTENTIAL CLINICAL SITES IN THE US
    * OX400: EXPECTS TO SELECT THE OPTIMIZED COMPOUND AND ENTER
PRECLINICAL DEVELOPMENT IN 2022
    * PROJECTED ACTIVITY FOR OX400: DEVELOPMENT OF THE
TRANSLATIONAL
AND REGULATORY PLAN FOR ENTRY INTO THE CLINIC IN 2023
    * HAS NOT RECORDED ANY CONSOLIDATED REVENUES IN H1
    * H1 CURRENT OPERATING LOSS EUR 9.3 MLN VS LOSS OF EUR 4.7
MLN YR
AGO
    * H1 OPERATING LOSS AFTER SHARE OF PROFIT OF ASSOCIATES EUR
9.0
MLN VS LOSS OF EUR 4.5 MLN YR AGO
    * H1 NET LOSS EUR 11.5 MLN VS EUR 4.8 MLN YR AGO

        
 Source text for Eikon:  urn:newsml:reuters.com:*:nBwCQnM3a
 Further company coverage:  ALONX.PA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))